Checkmate Therapeutics
체크메이트테라퓨틱스
Seoul, South Korea · Founded 2019
- Headquarters
- Seoul
- Employees
- 1–10
- Founded
- 2019
- Business Model
- B2B
- Website
- checkmatetx.com
About
Checkmate Therapeutics is a Seoul-based biopharmaceutical company founded in 2019 focused on discovering and developing first-in-class therapies for metastatic and difficult-to-treat cancers. The company employs novel target-based drug discovery approaches to identify innovative therapeutics for patients suffering from cancer and other incurable diseases. Founded by Professor Hyun Seok Kim of Yonsei University College of Medicine, who serves as Founder and CSO, the company bridges academic oncology research with translational drug development. Checkmate Therapeutics operates at the early stage of the drug discovery pipeline with a focus on targeted cancer therapies.
Summary
Checkmate Therapeutics is a Biotech company based in Seoul, South Korea, founded in 2019.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...

IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...

Specialty pharmaceutical company
Altos Labs combines academic science and industry development to create medicines that restore ce...
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/checkmate-therapeutics"><img src="https://indexed.vc/api/badge/company/checkmate-therapeutics" alt="Checkmate Therapeutics on Indexed.vc" width="260" height="76" /></a>